InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.012 -0.248 (-95.38%)+
Announcement
Release
12 Jun 2026 9:46AM
Price at Release
$0.260
Full Release
download
Summary
Cynata Therapeutics Limited has requested a trading halt for its securities, effective 12 June 2026, pending a significant announcement regarding the results of its Phase 3 Osteoarthritis Trial and Phase 2 Graft Versus Host Disease Trial. This halt will remain in place until the company releases the announcement or until the commencement of normal trading on 16 June 2026, whichever comes first. The company confirms that it is unaware of any reasons why this trading halt should not be granted and states that the halt is in line with ASX Listing Rule 17.1.
Key Points
  • Cynata Therapeutics Limited requests trading halt for its securities.
  • Trading halt pending announcement of clinical trial results.
  • Phase 3 Osteoarthritis Trial and Phase 2 Graft Versus Host Disease Trial results pending.
  • Trading halt to last until 16 June 2026 or earlier announcement.
  • Company not aware of reasons against trading halt.
  • Trading halt in accordance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.